Navigation Links
STERIS Corporation Announces Quarterly Dividend Increase of 38%
Date:5/7/2009

MENTOR, Ohio, May 7 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today announced that its Board of Directors has authorized a 38% increase in its quarterly dividend to $0.11 per common share. The dividend is payable June 18, 2009 to shareholders of record at the close of business on May 21, 2009.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company's more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.

This news release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "confidence," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any future dividend payment or other financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, regulatory actions, including without limitation previously disclosed FDA warning letters and government investigations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, and (f) the possibility that anticipated cost savings may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release may adversely impact Company performance, results, or value.


'/>"/>
SOURCE STERIS Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
2. STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call
3. STERIS Corporation Announces Fiscal 2008 Second Quarter Results
4. STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call
5. STERIS Corporation Declares Regular Quarterly Dividend
6. STERIS Corporation Announces Fiscal 2008 Third Quarter Results
7. STERIS Corporation Promotes Timothy L. Chapman to Group President of Healthcare
8. STERIS Corporation Announces New $300 Million Share Repurchase Authorization
9. STERIS Corporation Names Michael J. Tokich Chief Financial Officer
10. STERIS Corporation Declares Regular Quarterly Dividend
11. Steris Corporation Announces the Appointment of Two New Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... ... Zifam Pinnacle, an Australian company dedicated to providing a unique range of ... the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle develops products ... of its creations to help create a more traditional and natural approach to healthy ...
(Date:1/21/2017)... ... 2017 , ... Caronlab Australia, an Australian company known for health and beauty ... Head, SC, where it benefited from outstanding meetings with major retail buyers. , Caron ... products. At this trade show, the company had the chance to demonstrate its products ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats ... of its owner and founder. As Oat is recognized globally as one of the ... personally as he believes it is a move to sow the seed of good ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... Redwood Family Dermatology has recently joined their multi-specialty medical group. The ... range of cosmetic services. , “We’re excited to add this excellent dermatology practice ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Periodontist Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative ... by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Wells Specialty Pharmacy announces the acquisitions and merger ... Winter Park, Florida and Pharm-EZ Medical, ... have been consolidated into the 3796 Howell Branch Road Facility. ... that Chad Tomlinson , former Vice President of Operations, ... Mr. Tomlinson is a Graduate of Florida State University and ...
(Date:1/19/2017)... -- Germany Cataract Surgery Devices Market ... "Germany Cataract Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic Devices ... distribution shares data for each of these market segements, ...
(Date:1/19/2017)... 2017 The Global Therapy Partnering Terms and ... partnering deals and agreements entered into by the world,s ... - Top deals by value - Deals listed by ... The report provides understanding and access to the ... leading healthcare companies. The report provides an analysis ...
Breaking Medicine Technology: